were isolated from the leaves of Thevetia peruviana SCHUM., together with nine known flavonol glycosides and two known iridoid glucosides. The structures of all compounds were determined on the basis of chemical and spectroscopic methods. Their inhibitory effects against HIV-1 reverse transcriptase and HIV-1 integrase were also investigated.
The acquired immunodeficiency syndrome (AIDS) is caused by human immunodeficiency virus and remains one of the leading causes a crisis worldwide in public health. HIV-1 encodes three enzymes, protease (PR), reverse transcriptase (RT) and integrase (IN). HIV-1 PR processes viral proteins into functional enzymes and structural proteins. HIV-1 RT is the multifunctional enzyme that transcripts viral RNA into viral DNA which is important for viral replication, whereas IN is responsible for the integration of double strand DNA transcribed from viral RNA into the host chromosome. For HIV-1 PR, many inhibitors have been prepared chemically and used intensively for AIDS treatments. However, their use is limited due to the emergence of drug resistance and toxicity. 1) Thus, screening of natural products provides an opportunity for the discovery of HIV-1 IN and HIV-1 RT inhibitors.
Thevetia peruviana SCHUM. is an evergreen flowering shrub belonging to the Dogbane family, Apocynaceae. It grows widely throughout tropical and subtropical regions. Its generic name is yellow oleander.
2) The latex of the oleander is poisonous to man, animals and certain insects. Despite its toxicity, oleander has been used as an abortifacient, to treat congestive heart failure, malaria, leprosy, indigestion, ringworm, venereal disease and even as a suicide instrument.
3)
The leaves have been reported to contain iridoid glycosides, 4) flavonoids, 5) triterpenes, 6) monoterpenes 7) and cardiac glycosides. 8) From the screening of Thai medicinal plants against HIV-1, an ethanol (EtOH) extract of T. peruviana showed high anti HIV-1 (IC 100 ϭ1.56 mg/ml) and HIV-1 IN inhibitory activity (IC 50 ϭ12.0 mg/ml).
9) Therefore, the EtOH extract of this plant was fractionated further into n-hexane, chloroform (CHCl 3 ), and water (H 2 O) soluble fractions. In this paper, we describe the structure elucidation of new compounds from the water fraction and the inhibitory activities against HIV-1 IN and HIV-1 RT-associated DNA polymerase [RNA-dependent DNA polymerase (RDDP) and DNA-dependent DNA polymerase (DDDP)] of the isolated compounds.
Results and Discussion
An EtOH extract of the leaves of T. peruviana was concentrated and partitioned with n-hexane, CHCl 3 and H 2 O. The H 2 O soluble fraction was repeatedly chromatographed over normal and reversed-phase silica gel to afford two iridoid glucosides (1, 2), two flavanone glucosides (3, 4) and ten flavonol glycosides (5-14) (Chart 1). The known compounds were identified as theviridoside (1), 4) theveside (2), 4) quercetin 12) and (14) . 13) Of these flavonol glycosides, five compounds (9, 10, 11, 12 and 14) were isolated for the first time from this plant species. The structures of the new compounds were determined as follows:
Compound 3 (peruvianoside I), a white amorphous powder, showed quasi-molecular ion peaks [MϪH] Ϫ at m/z 493 in the negative ion fast atom bombardment mass spectrum (FAB-MS) and [MϩH] ϩ at m/z 495 in the positive ion FAB-MS spectrum, suggesting the molecular formula of C 23 ϩ was also observed in both positive ion FAB-MS and electron impact (EI)-MS. The infrared (IR) spectrum showed the presence of a carbonyl group at 1652 cm
Ϫ1
, and hydroxyl groups at 3448 cm
. Ultraviolet (UV) absorption bands at 210 (e 35000), 283 (e 15000) and 325 (sh) were similar to those of flavanones.
14) 15) On acid hydrolysis, 3 afforded D-glucose which was identified by co-thin layer chromatography (TLC) and gas chromatography (GC)-MS comparing with those of an authentic sample. 16) In the 13 C-NMR spectrum, signals at d 80.2 and 46.3 were assigned to C-2 and C-3 of the dihydropyrone moiety, 14) whereas that at d 56.5 was assigned to methoxyl groups ( Table 1 ). The sugar linkage was determined by the heteronuclear multiple bond coherence (HMBC) experiment; a long-range coupling observed between a carbon signal at d 165.0 (C-5) and a proton signal at d 5.47 (glc-1) revealed glycosylation at C-5 with a glucose unit. This was also supported by the upfield shift of C-4 to d 190.5, indicating the absence of intramolecular hydrogen bonding between a carbonyl group at C-4 and a hydroxyl group at C-5, thereby implying the linkage of glucose at C-5. 14) A carbon signal at d 166.4 (C-7) was correlated with both signals at d 6.62 (H-6) and d 7. 3 ) indicated the structure of S-configuration at C-2 by comparison with the previous report. 17) From the above evidence, compound 4 was determined to be (
Compound 13 (peruvianoside III), a yellow amorphous powder, gave a quasi-molecular ion peak [MϪH] Ϫ at m/z 771 in the negative ion FAB-MS and was assigned the formula , aromatic groups at 2922 cm Ϫ1 and hydroxyl groups at 3422 cm
. The UV absorption bands at 210 (e 29000), 255 (e 18000) and 355 (e 14000) suggested it to be a flavonol analogue.
14) The 1 H-NMR spectrum of 13 showed characteristics of a quercetin moiety. 5 Table 2 , a signal which shifted downfield of d 82.6 was assigned to C-2 of galactose, while that of the downfield shift of d 66.0 was assigned to C-6 of galactose. In the HMBC spectrum, significant cross peaks were observed between an anomeric proton signal of glucose (d 5.41) and a C-2 signal of galactose (d 82.6), along with a cross peak between an anomeric proton signal of rhamnose (d 5.11) and a C-6 signal of galactose (d 66.0). Thus, the structure of 13 was determined to be
Of the isolated compounds from T. peruviana, compounds 7, 9, 11, 14 and quercetin showed appreciable HIV-1 RDDP inhibitory activity with IC 50 values of 33, 20, 41, 38 and 43 mM, respectively, whereas the others showed moderate or no activity. As to the structure-activity relationships, it was 632 Vol. 50, No. 5 Table 3 ).
In the case of HIV-1 IN inhibitory activity, compound 9 again showed the highest activity (IC 50 ϭ5 mM) among the isolated compounds, followed by 7, 8, 10, 14, 11 and 6 with IC 50 values of 7, 30, 31, 43, 45 and 59 mM, respectively. Compounds possessing a feruloyl or sinapoyl group in the terminal glucose moiety showed more potent inhibitory activity than unsubstituted ones, when the IC 50 values of 7 and 8 (or 9 and 10) were compared with those of 5 and 6. These compounds also showed higher inhibitory activity than their aglycones quercetin and kaempferol. Moreover, compounds that inhibited HIV-1 IN activity also possessed HIV-1 RDDP inhibitory activity, although they did not appreciably affect DDDP activity. Flavanone glucosides 3, 4 and iridoid glucosides 1, 2, showed no activity at concentrations below 100 mM against either HIV-1 RT or HIV-1 IN (Table 3) .
As regards the bioactivities of flavonol glycosides, quercetin and kaempferol 3-O-[(6-feruloyl)-glucopyranosyl-galactopyranoside] were reported to show neuroprotective activity in primary cultures of rat cortical cells damaged by L-glutamate, 18) whereas quercetin 3-O-[(6-feruloyl)-galactopyranoside] exhibited anti-superoxide production, 19) and anticomplement effects. 20) Feruloyl and sinapoyl glycosides showed radical scavenging activities against a 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical and inhibitory activity against the oxidation of linoleic acid. 21) In 1998, Kim et al. were previously reported to show antiherpetic activity by inhibition of the plaque formation of HSV-1 and HSV-2, 23) and also possessed the hepatoprotective activity. 24) In 1997, Min et al. reported that the dimethyl ethers of flavanones exhibited significant cytotoxic activity against a human leukemia cell line and a human lung carcinoma cell line.
25)

Experimental
General Melting points were measured on a Yanagimoto micro hotstage melting point apparatus. Optical rotations were measured with a DIP-360 automatic polarimeter (Jasco Co., Tokyo, Japan). UV spectra were measured with a SHIMADZU UV-2200 (Shimadzu Co., Kyoto, Japan). CD spectra were measured with a JASCO J 805 spectropolarimeter (Jasco Co.) and IR spectra were measured with a JASCO FT/IR-230 infrared spectrometer.
1 H-and . FAB-MS were obtained with a JEOL JMS-DX 300L spectrometer using glycerol as a matrix. HR-FAB-MS were measured with a JEOL JMS-700T mass spectrometer with a resolution of 5000 and glycerol containing a faint amount of NaCl. GC-MS was performed on a SHIMADZU GC-17A instrument and a JEOL automass system II. BIORAD, model 1250 immunowash (Biorad Co., California, U.S.A.); KUBOTA 6800, rotator (Kubota Co., Osaka, Japan); and ADVANTEC, CI-410 incubator (Advantech Co., Tokyo) were used for the multiplate integration assay.
Column chromatography was carried out on silica-gel BW-820 MH, ODS (Fuji Silysia Chemical Co., Nagoya, Japan), Diaion HP-20 (Mitsubishi Chemical Co., Tokyo), Sephadex LH-20 (Pharmacia Co., Tokyo, Japan) and Amberlite MB-3 (Organo Co., Tokyo). Preparative HPLC was carried out on a TOSOH CCPM-II system (Tosoh Co., Tokyo) equipped with a UV 8020 detector and a TSK gel ODS-80Ts column (21.5ϫ300 mm, Tosoh Co., Tokyo). Analytical TLC was carried out on pre-coated silica-gel 60 F 254 plates (0.25 mm, Merck Co., Darmstadt, Germany) and RP-18 F 254 S plates (0.25 mm) and spots were detected under UV light or after spraying with anisaldehyde-5% H 2 SO 4 .
Plant Material The leaves of T. peruviana were collected at the Botanical Garden of the Department of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand in August, 2000. The voucher specimen (SKP 0132016) is deposited at the Herbarium of the Faculty of Pharmaceutical Sciences, Prince of Songkla University.
Isolation of Compounds 1-14 from the Leaves of T. peruviana
The dried powdered leaves (5.0 kg) were extracted with EtOH 6 times at room temperature. An EtOH extract was then concentrated and partitioned between MeOH and n-hexane, and the MeOH-soluble fraction was subsequently partitioned with CHCl 3 and H 2 O. The respective fractions were evaporated to dryness in vacuo to give residues of 87.7, 51.5 and 98.6 g as hexane, CHCl 3 and H 2 O soluble fractions. The H 2 O fraction was chromatographed on Diaion HP-20 and eluted consecutively with water, 50% MeOH I, 50% MeOH II and 100% MeOH to give the respective fractions of 55.8, 2.2, 29.9 and 6.6 g after evaporation of solvent.
The fraction eluted with 50% MeOH I (1.1 g) was chromatographed on ODS (2.5ϫ50 cm.) with MeOH-H 2 O (1 : 5) to give 4 fractions (fr. I-1 to fr. I-4). Fraction I-2 (0.2 g) was further chromatographed on silica gel (2.0ϫ50 cm) with a solvent system of CHCl 3 -MeOH (2 : 1) to afford compound 2 (134 mg), whereas fraction I-4 gave compound 1 (164 mg).
The fraction eluted with 50% MeOH II (10.0 g) was passed through a silica gel column (5.0ϫ60 cm) with CHCl 3 -MeOH (4 : 1→1 : 1) to give 3 fractions (fr. II-1 to fr. II-3). Fr. II-2 yielded compound 1 (5.41 g), while fr. II-3 (2.4 g) was chromatographed further using a Sephadex LH-20 column (3.0ϫ50 cm) with MeOH-CHCl 3 (9 : 1) to afford four fractions (fr. II-3a to fr. II-3d). Fraction II-3c (0.53 g) was subjected to prep. HPLC (40% MeOH in 0.1% TFA/H 2 O, 5 ml/min, monitored at 254 nm) to give compounds 13 (10.8 mg), 14 (4.2 mg), mixture A (78.0 mg) and mixture B (39.1 mg). Mixture A was further chromatographed by prep. HPLC (13% CH 3 CN in 0.1% TFA/H 2 O, 5 ml/min, monitored at 254 nm) to obtain compounds 5 (9.7 mg) and 11 (11.4 mg) . Meanwhile, mixture B (39.1 mg) was subjected to prep. HPLC using 13% CH 3 CN in 0.1% TFA/H 2 O as a mobile phase, to give compounds 6 (6.2 mg) and 12 (6.4 mg).
The fraction eluted with 100% MeOH (3.0 g) was passed through a Sephadex LH-20 column (4.0ϫ50 cm) with MeOH-CHCl 3 (9 : 1) to give 13 C-NMR: Table 1 Quercetin 13 C-NMR data: see Table 2 . Acid Hydrolysis of 13 Compound 13 (1 mg) was refluxed with 7% HCl in H 2 O-EtOH (1 : 1, 1 ml) for 3 h. The reaction mixture was partitioned between CHCl 3 RDDP Inhibitory Activity Assay For the assay of RDDP inhibitory activity, 26, 27) HIV-1 RT was adjusted to 0.01 U/ml with a solution of 0.2 M phosphate buffer (pH 7.2), 50% glycerol, 2 mM dithiothreitol (DTT) and 0.02% of Triton X-100. A reaction mixture (20 ml) containing 50 mM Tris-HCl (pH 8.3), 30 mM NaCl, 10 mM MgCl 2 , 5 mM DTT, 1.25 mg/ml (ca. 16 nM) poly(rA).oligo(dT) [12] [13] [14] [15] [16] [17] [18] as a template primer, 250 nM dTTP, 100 nM [methyl-3 H]dTTP (18.5 MBq/ml), 0.01 U/ml of RT, and 1.0 ml of a test compound dissolved in dimethyl sulfoxide (DMSO) (final concentration of 5%) was incubated at 37°C for 1 h. A control reaction was done under the same conditions without adding the test compound. The reaction was terminated by the addition of 20 ml of 0.02 M EDTA. The resulting mixture was applied to a Whatman DE 81 paper disc and washed batchwise with 3 ml of 5% Na 2 HPO 4 , distilled water 3 times, ethanol once and ether once. The paper disc was then dried and immersed in 3 ml of scintillation fluid. The amount of polymer fraction, including 3 H-labeled residues, was determined by counting the radioactivity on the paper disc. The calculation of the inhibitory potency for the tested compound was done as follows:
Adriamycin (Sigma-Aldrich Co., Tokyo) was used as a positive control, and inhibited RDDP activity with an IC 50 value of 27 mM under the above conditions.
DDDP Inhibitory Activity Assay For the assay of DDDP inhibitory activity, HIV-1 RT was adjusted to 0.1 U/ml with a solution of 0.2 M phosphate buffer (pH 7.2), 50% glycerol, 2 mM DTT and 0.02% of Triton X-100. A reaction mixture (20 ml) containing 50 mM Tris-HCl (pH 8.3), 30 mM NaCl, 10 mM MgCl 2 , 5 mM DTT, 1.25 mg/ml (ca. 16 nM) poly(dA).oligo(dT) [12] [13] [14] [15] [16] [17] [18] as a template primer, 250 nM dTTP, 200 nM [methyl-
3 H]dTTP (18.5 MBq/ml), 0.1 U/ml of RT, and 1.0 ml of a test compound dissolved in DMSO (final concentration of 5%) was incubated at 37°C for 1 h. A control reaction was done under the same conditions without adding the test compound. The reaction was terminated by the addition of 20 ml of 0.02 M EDTA. The resulting mixture was applied to a Whatman DE 81 paper disc and washed in a similar manner as described for RDDP. The amount of a polymer fraction, including 3 H-labeled residues, was determined by counting the radioactivity on the paper disc. Calculation of the inhibitory potency for the tested compound was done as follows:
Adriamycin was used as a positive control, and inhibited DDDP activity with an IC 50 value of 6 mM under the above conditions. HIV-1 IN Inhibitory Activity Assay. a) HIV-1 IN HIV-1 IN protein was expressed in Escherichia coli and purified, and was stored at Ϫ80°C before use.
b) Oligonucleotide Substrates Oligonucleotides of long terminal repeat (LTR) donor DNA and substrate DNA were purchased from Japan Bioservice (JBios) (Asaka city, Japan) and stored at Ϫ25°C before use. The sequences of the biotinylated LTR donor DNA were 5Ј-biotin-ACC CTT TTA GTC AGT GTG GAA AAT CTC TAG CAG T-3Ј and its unlabelled complement 3Ј-GAA AAT CAG TCA CAC CTT TTA GAG ATC GTC A-5Ј, and those of the substrate DNA (digoxigenin-labelled target DNA) were 5Ј-TGA CCA AGG GCT AAT TCA CT-digoxigenin and its 3Ј-labelled complement, digoxigenin-ACT GGT TCC CGA TTA AGT GA-5Ј. c) Multiplate Integration Assay (MIA) Procedure This assay using a 96-well plate was basically similar to that reported by Hazuda et al. 28) First, a 96-well plate was coated with 50 ml of a streptavidin solution containing 40 mg/ml streptavidin, 90 mM Na 2 CO 3 and 10 mM KCl. Fifty microliters of a biotinylated LTR donor DNA solution containing 10 mM Tris-HCl (pH 8.0), 1 mM NaCl and 40 fmol/ml of LTR donor DNA were added to each well, and the plate was shaken gently at room temperature for 30 min, then washed with phosphate buffer saline (PBS) (pH 7.3), 4 times. A mixture (45 ml) composed of 12 ml of 5ϫIN buffer [containing 150 mM 3-(N-morpholino)-propane sulfonic acid (MOPS) (pH 7.2), 75 mM MnCl 2 , 5 mM DTT, 25% glycerol and 500 mg/ml bovine serum albumin], 1 ml of 5 pmol/ml digoxigenin-labelled target DNA and 32 ml of sterilized water was added to each well. Subsequently, 6 ml of a sample solution and 9 ml of a 1/10 dilution of integrase enzyme were added to the plate and the mixture was incubated at 37°C for 80 min. The wells were washed with PBS 4 times, then 100 ml of 500 mU/ml alkaline phosphatase (AP) labelled anti-digoxigenin antibody was added and incubation followed at 37°C for 1 h. The plate was washed again with washing buffer containing 0.05% Tween 20 in PBS 4 times and with PBS 4 times. Then, AP buffer (150 ml) containing 100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 5 mM MgCl 2 and 10 mM p-nitrophenyl phosphate was added to each well and they were incubated at 37°C for 1 h. Finally, the visible absorbance of each well was measured with a microplate reader (BIO-RAD, model 3550 UV) at a wavelength of 405 nm. The positive control was composed of the reaction mixture, 50% DMSO and an integrase enzyme, while the negative control was buffer-E containing 20 mM MOPS (pH 7.2), 400 mM potassium glutamate, 1 mM ethylenediaminetetraacetate disodium salt (EDTA.2Na), 0.1% Nonidet-P 40 (NP-40), 20% glycerol, 1 mM DTT and 4 M urea without the integrase enzyme. Suramin was used as a positive control, which inhibited the IN activity with an IC 50 value of 2.4 mM under the above conditions.
